February 26, 2025

Oklahoma Senate
Business and Insurance Committee
2300 North Lincoln Boulevard
Oklahoma City, Oklahoma 73105

Dear Senator,

On February 27, 2025, the Senate Committee on Business and Insurance will hold a hearing on SB 1030.  On behalf of 23,276 members and supporters of the Council of Citizens Against Government Waste (CCAGW) in Oklahoma, I urge you to oppose SB 1030, which will change how the federal 340B Drug Pricing Program operates in Oklahoma. 

A November 2021 Xcenda study, “340B and Health Equity: A Missed Opportunity in Medically Underserved Areas,” showed how 340B boosts hospitals’ coffers and their contract pharmacies’ profits located in areas that do not serve low-income people.  An IQVIA study, “The 340B Drug Discount Program Exceeds $100B in 2022,” found ongoing misuse of the funds by hospitals and contract pharmacies.

A January 23, 2025, fiscal analysis of 340B contract pharmacy mandate legislation in Utah found that, “Enactment of this legislation could also increase pharmacy costs for the Public Employees Health Program (PEHP).  Assuming ten percent more drugs are purchased through 340B pricing, PEHP statewide costs could increase by $1,987,700, ongoing in FY 2026 from the General Fund, Income Tax Fund and Other Financing Sources.”  There is no reason to risk Oklahoma taxpayers’ money by enacting SB 1030.

On November 25, 2024, the Minnesota Department of Health (DOH) issued the first report on how 340B works in a state.  The hospitals received at least $630 million in 340B revenue in 2023, which may only be half of the total.  The largest hospitals, or 13 percent of participating hospitals, received more than $500 million, or 80 percent of the revenue.  The highest profit was $129 million at M Health Fairview University of Minnesota Medical Centers while federal safety-net grantee clinics generated the least revenue.  The Minnesota DOH report should be a wake-up call not only for Congress to move forward with 340B reform as CCAGW has recommended, including defining a patient as indigent, not eligible for Medicaid, and lacking insurance, as well as verification of patient eligibility by covered entities, but also for states like Oklahoma to forgo changes to the program at least until they analyze how it is impacting patients and taxpayers within their borders.

For the above reasons, I ask you to oppose SB 1030 and rather than acting on legislation that impacts a federal program, I urge you to contact your congressional delegation and ask them to reform 340B.   

Sincerely,
Tom Schatz
President, CCAGW